| Preview | Issue Date | Title / Name | Author(s) | Type |
| 2020 | Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2+/HR+ metastatic breast cancer | Loft, Matthew; Lok, Sheau Wen; De Boer, Richard H.; Malik, Laeeq; Greenberg, Sally, et al | Journal Article | |
| Jan-2023 | Addition of endocrine therapy to dual anti-HER2 targeted therapy in initial treatment of HER2 + /HR + metastatic breast cancer | Loft, Matthew; Lok, Sheau Wen; De Boer, Richard; Malik, Laeeq; Greenberg, Sally, et al | Journal Article | |
| 2018 | Cardiotoxicity in advanced HER2 positive breast cancer in real world Australian patients receiving HER2-targeted therapy in the first-line setting | Conduit, C.; King, Rossa; De Boer, Richard; Gibbs, Peter; Lok, Sheau Wen, et al | Conference Paper | |
| 2022 | CDK4/6 Inhibitors (CKD4/6i) in advanced hormone-receptor-positive (HR+) HER2-negative (HER2-) breast cancer: Prescribing practices and outcomes in a real-world, Australian cohort | Javaid, Anadil; Lok, Sheau Wen; Wong, Vanessa; Baron-Hay, Sally; Boyle, Fran, et al | Conference Paper | |
| Nov-2020 | Impact of prior (neo)adjuvant trastuzumab (NAT) exposure on the efficacy of HER2-targeted therapy for metastatic breast cancer | Collins, Ian M.; Kanjanapan, Yada; Wen Lok, Sheau; Gibbs, Peter; De Boer, Richard, et al | Journal Article | |
| 2018 | Management of brainmetastases in patients with HER2 positive breast cancer-a real world Australian experience | Moldovan, Cristina A.; King, Rossa; Lok, Sheau Wen; De Boer, Richard; Gibbs, Peter, et al | Conference Paper | |
| 2020 | Real world outcomes in elderly patients with HER2 positive advanced breast cancer | Evans, Nicole; Anton, Angelyn; Wong, Rachel; Lok, Sheau Wen; De Boer, Richard, et al | Conference Paper | |
| 2021 | Real world outcomes in elderly women with HER2 positive advanced breast cancer | Evans, Nicole; Anton, Angelyn; Wong, Rachel; Lok, Sheau Wen; De Boer, Richard, et al | Conference Paper | |
 | 2020 | Real World Outcomes in Elderly Women with HER2-Positive Advanced Breast Cancer | Evans, Nicole; Anton, Angelyn; Wong, Rachel; Lok, Sheau Wen; De Boer, Richard, et al | Conference Paper | |
| 2020 | Real-world impact of anti-HER2 therapy-related cardiotoxicity in patients with advanced HER2-positive breast cancer | Conduit, C.; de Boer, R. H.; Lok, S.; Gibbs, Peter; Malik, Laeeq, et al | Journal Article | |
| 2021 | Real-world outcomes in patients with brain metastases secondary to HER2-positive breast cancer: An Australian multi-centre registry-based study | Tung, Iris; Moldovan, Cristina; Wong, Vanessa; De Boer, Richard; Gibbs, Peter, et al | Conference Paper | |
| Oct-2022 | Real-World Outcomes in Patients With Brain Metastases Secondary to HER2-Positive Breast Cancer: An Australian Multi-centre Registry-based Study | Tung, Iris; Moldovan, Cristina; Wong, Vanessa; De Boer, Richard; Yeo, Belinda, et al | Journal Article | |
| 2020 | Real-world uptake of bone modifying agents in advanced breast cancer with bone metastases-Prospective data from a multi-site Australian registry | Wong, Vanessa; De Boer, Richard; Anton, Angelyn; Malik, Laeeq; Greenberg, Sally, et al | Conference Paper | |
| 2021 | Uptake of bone-modifying agents in patients with HER2+ metastatic breast cancer with bone metastases - prospective data from a multi-site Australian registry | Wong, Vanessa; de Boer, Richard; Dunn, Catherine; Anton, Angelyn; Malik, Laeeq, et al | Journal Article | |
